--- canonical_url: https://www.stockexpertai.com/earnings/zts last_updated: 2026-05-05T21:40:59.198Z --- # Zoetis Inc. (ZTS) Q4 FY2026 Earnings Preview > **[stale-preview-note]** Note: this preview was published before the 2026-05-07 earnings report. Results have since been released — verify against the latest filings. > This content was automatically generated with FMP live data + Q4 FY2025 earnings call transcript. Generated: 2026-05-05T21:40:58.975Z. Educational tool, not investment advice. --- ## Quick Summary | Field | Value | Source | |---|---|---| | Price | $112.54 (▼ -0.12%) | fmp:quote | | Market Cap | $47.5B | fmp:profile | | 52w range | $111.27 – $172.23 | fmp:quote | | Earnings | Thu 7 May | fmp:earnings-history | | EPS estimate | $1.61 (+9% YoY) | fmp:earnings-estimate | | Revenue estimate | $2.3B | fmp:earnings-estimate | | Beat streak | 8/4 | fmp:earnings-history | | Rating | B+ (overall 3/5) | fmp:ratings | | Analyst median target | $138 (+22.6% upside) | fmp:price-target-consensus | | MoonshotScore | 56/100 | derived | | Council | 2/6 bullish | derived | | Munger verdict | Fairly Valued | derived | ## Zoetis Inc. — Q4 FY2026 Expectations Q4 consensus: revenue $2.3B^{[FMP est]}, EPS $1.61^{[FMP est]}. 8 consecutive quarters of beat^{[FMP earnings]}. ## Quick Take **Score:** B+ · **Stance:** BUY · **Council:** 2/6 · **Moonshot:** 56 = MoonshotScore 56^{[9-pillar formula]} + Council 2/6^{[6-lens rule]}. Form 4: 0 transactions^{[FMP Form 4]}. ## Watchlist (6 metrics) ### 1. Dermatology Franchise Growth Our key dermatology franchise grew 6% operationally for the year with strong international contributions, reflecting the durability of the category we built. > "Our key dermatology franchise grew 6% operationally for the year with strong international contributions, reflecting the durability of the category we built." > — Kristin Peck, Investor Focus · Q4 FY2025 ### 2. Companion Animal Diagnostics Growth Companion animal diagnostics delivered broad-based 13% operational revenue growth for the year, even with ongoing pressure on clinic visits. > "Companion animal diagnostics delivered broad-based 13% operational revenue growth for the year, even with ongoing pressure on clinic visits." > — Kristin Peck, Investor Focus · Q4 FY2025 ### 3. Simparica Franchise Growth The Simparica franchise grew 12% operationally for the year, with double-digit performance in both the U.S. and International markets. > "Our Simparica franchise grew 12% operationally for the year, with double-digit performance in both the U.S. and International markets." > — Kristin Peck, Investor Focus · Q4 FY2025 ### 4. Livestock Growth We delivered 8% organic operational revenue growth for the year, with especially strong double-digit contribution internationally. > "We delivered 8% organic operational revenue growth for the year, with especially strong double-digit contribution internationally." > — Kristin Peck, Investor Focus · Q4 FY2025 ### 5. Oa Pain Decline Turning to OA pain. The franchise declined 3% operationally for the year, and we remain committed to returning it to growth. > "Turning to OA pain. The franchise declined 3% operationally for the year, and we remain committed to returning it to growth." > — Kristin Peck, Investor Focus · Q4 FY2025 ### 6. Simparica Trio Performance Trio continued to be a key driver, growing 13% operationally. In the U.S. sales surpassed $1 billion with continued gains at initiation and the highest puppy share in the clinic. > "Trio continued to be a key driver, growing 13% operationally. In the U.S. sales surpassed $1 billion with continued gains at initiation and the highest puppy share in the clinic." > — Kristin Peck, Investor Focus · Q4 FY2025 ## MoonshotScore Pillars | Pillar | Score | Level | Evidence | |---|---|---|---| | Revenue Growth | 4.0 | medium | Q4 vs Q1: moderate growth (+7.5%) | | Gross Margin | 7.0 | strong | Q4: very high margin (68.9%, software/cloud territory) | | Operating Leverage | 3.0 | weak | op margin very strong (34.6%, scale leverage) | | Cash Runway | 10.0 | strong | FCF very strong ($0.7B, 4.5× CapEx) | | R&D Intensity | 5.0 | medium | average R&D (7.4%) | | Price Momentum | 4.0 | medium | RSI 37.4 weak momentum, 50d below | | News Sentiment | 6.0 | medium | majority buy (62%) | **Formula:** sum(pillar.score) / (count * 10) * 100. Each pillar deterministic from FMP. Source maps in pillar.formula. ## Council (7-Lens) | Name | Stance | Context | |---|---|---| | Ray Dalio | bull | macro · target upside +22.6% | | Ken Griffin | bear | flow · 50d MA below | | Jim Simons | neutral | quant · RSI 37 | | Klarman | neutral | value · target upside +22.6% | | Buffett | bull | quality · ROE score 5/5 | | Munger | neutral | valuation · target upside +22.6% | **Formula:** Each lens uses deterministic rule on bundle data. Logged in member.contextTr. ## Munger Lens - **Verdict:** Fairly Valued - **Financial Health:** Moderate - **Margin of Safety:** Moderate - **Interest Coverage:** Adequate - **ROIC vs WACC:** Healthy **Formula:** verdict=upside>25?Undervalued:>0?Fairly Valued:Overvalued. Each lens deterministic from FMP ratings + priceTarget. ## Technical Levels - **RSI(14):** 37.4 — momentum zayıf — oversold yakınında değil ama alıcı baskısı az - **50d MA:** $119 — hisse %5.6 altında — kısa vadeli direnç - **200d MA:** $132 — hisse %14.6 altında — uzun vadeli baskı - **Volume (10d):** -6% ## Past Performance (4 Quarters) | Quarter | EPS Actual | EPS Estimate | Result | Reaction | |---|---|---|---|---| | Q1 FY25 | $1.48 | $1.41 | BEAT | +4.1% | | Q2 FY25 | $1.76 | $1.62 | BEAT | +0.3% | | Q3 FY25 | $1.70 | $1.62 | BEAT | -3.2% | | Q4 FY25 | $1.48 | $1.40 | +5.7% EPS | +0.8% | Q4 (February 12, 2026): EPS $1.48 vs $1.40 est^[FMP], +5.7% beat. D+1 movement: +0.8%^{[FMP D+1]}. Decline despite beat — market reacted to guidance, not numbers. ## 3 Scenarios ### Scenario A · Beat **Q4 EPS > $1.61 + Companion Animal ≥ 5%** Threshold: EPS > $1.61^{[FMP est]} and Companion Animal ≥ 5%^{[Wetteny Joseph transcript]}. Target: Break above median target $138^{[FMP target]}; high target $160^[FMP] upper bound. ### Scenario B · In-Line **EPS ≈ $1.61 + Companion Animal 3-5% + CapEx promise kept** Threshold: EPS ≈ $1.61^{[FMP est]}, Companion Animal 3-5%, Q4 CapEx < $161.0M^[FMP]. Target: Consolidation in the band between current $113^[FMP] and median $138^[FMP]. ### Scenario C · Miss **EPS < $1.56 or Companion Animal < 35% or CapEx ≥ $161.0M** Threshold: EPS < $1.56^{[FMP est×0.97]} or Companion Animal < 35%^{[Wetteny Joseph guidance lower minus 2]}. Target: Current $113 below SMA200 $132^[FMP], if rejection continues, $112^[derived] support activates. ## Risk Notes ### Primary segment below threshold Q4: EPS $1.48 vs $1.40 beat^[FMP], stock +0.8% D+1^[FMP]. Wetteny Joseph Q4 transcript: "Looking ahead to 2026, we are guiding to a range of 3% to 5% organic operational revenue growth and expect 3% to 6% organic operational growth in adjusted net income."^{[Wetteny Joseph]}. ### Backlog concentration No RPO/backlog concentration disclosed in Q4 earnings call. ### Insider trading Form 4 data is marked in the table — this page does not generate assumptions for this stock. | Executive | Action | Amount | Date | |---|---|---|---| **Net:** — (0 transactions · 0 sells · 0 buys) · Q4 FY25 ### CapEx shock Q4 CapEx $161.0M^{[FMP cashflow]}. Q4 op margin 34.6%^{[FMP op margin]} — this level in Q4 is sensitive to CapEx revision risk. ## Wall Street Consensus - **Median target:** $138 (+22.6% upside vs current $113) - **High / Low:** $160 / $130 - **Buy / Hold / Sell:** 13 / 8 / 0 - **Analyst count:** 2 (last quarter), 22 all-time ## Additional Transcript Insights ### 1. simparica_franchise_growth **Claim:** The Simparica franchise grew 12% operationally for the year, with double-digit performance in both the U.S. and International markets. **Evidence (transcript):** "Our Simparica franchise grew 12% operationally for the year, with double-digit performance in both the U.S. and International markets." **Numbers:** 12% ### 2. simparica_trio_performance **Claim:** Trio continued to be a key driver, growing 13% operationally. In the U.S. sales surpassed $1 billion with continued gains at initiation and the highest puppy share in the clinic. **Evidence (transcript):** "Trio continued to be a key driver, growing 13% operationally. In the U.S. sales surpassed $1 billion with continued gains at initiation and the highest puppy share in the clinic." **Numbers:** 13%, $1 billion ### 3. dermatology_franchise_growth **Claim:** Our key dermatology franchise grew 6% operationally for the year with strong international contributions, reflecting the durability of the category we built. **Evidence (transcript):** "Our key dermatology franchise grew 6% operationally for the year with strong international contributions, reflecting the durability of the category we built." **Numbers:** 6% ### 4. oa_pain_decline **Claim:** Turning to OA pain. The franchise declined 3% operationally for the year, and we remain committed to returning it to growth. **Evidence (transcript):** "Turning to OA pain. The franchise declined 3% operationally for the year, and we remain committed to returning it to growth." **Numbers:** 3% ### 5. companion_animal_diagnostics_growth **Claim:** Companion animal diagnostics delivered broad-based 13% operational revenue growth for the year, even with ongoing pressure on clinic visits. **Evidence (transcript):** "Companion animal diagnostics delivered broad-based 13% operational revenue growth for the year, even with ongoing pressure on clinic visits." **Numbers:** 13% ### 6. livestock_growth **Claim:** We delivered 8% organic operational revenue growth for the year, with especially strong double-digit contribution internationally. **Evidence (transcript):** "We delivered 8% organic operational revenue growth for the year, with especially strong double-digit contribution internationally." **Numbers:** 8% --- *Data source: FMP (live query, 2026-05-05), Q4 FY2025 earnings call transcript (Translated to EN with Gemini 2.0 Flash). Educational tool, not investment advice.*